Tonix Pharmaceutical

**jerez1** · 20/07/2020, 21:26:11

Lanzada, +80%

**jerez1** · 19/04/2021, 16:05:33

Tonix Pharma Stock Is Trading Higher On Expanding COVID-19 Candidate Portfolio With Sangivamycin Licensing Pact

Tonix Pharma Stock Is Trading Higher On Expanding COVID-19 Candidate Portfolio With Sangivamycin Licensing Pact - Tonix Pharmaceuticals (NASDAQ:TNXP)

https://www.benzinga.com/general/biotech/21/04/20678689/tonix-pharma-stock-is-trading-higher-on-expanding-covid-19-candidate-portfolio-with-sangivamycin-

**jerez1** · 27/04/2021, 11:53:19

Tonix Pharmaceuticals Holding Corp. ( NASDAQ: TNXP ) El Dr. Seth Lederman le dice a Proactive que la compañía biofarmacéutica en etapa clínica ha formado un acuerdo de licencia exclusivo para desarrollar un posible tratamiento para el coronavirus, TNX-3500, de OyaGen, Inc., una compañía de investigación de biotecnología preclínica. El Dr. Lederman dice que el TNX-3500 es '65 veces más potente 'que el Remdesivir de Gilead, in vitro, para inhibir el coronavirus. Agrega que el grupo está muy emocionado de trasladar TNX-3500 a estudios con animales y, posteriormente, a pruebas clínicas en humanos.

Tonix Pharmaceuticals forms exclusive licensing agreement develop a potential coronavirus treatment

https://www.proactiveinvestors.com/companies/news/947669/tonix-pharmaceuticals-forms-exclusive-licensing-agreement-develop-a-potential-coronavirus-treatment-947669.html

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) Dr Seth Lederman tells Proactive the clinical-stage biopharmaceutical company has formed an exclusive...

**Chess81** · 05/05/2021, 11:06:52

Buenas jerez,

Sigo las empresas que vas publicando y me parece interesante esta por el sector, podrías decir si crees que tiene mucho potencial? Vi que comentabas que te dedicabas a este sector.

Gracias.

**jerez1** · 05/05/2021, 14:46:41

Yo mantengo esta y biontech. Les sigo viendo potencial. Ya vendí con grandes revalorizaciones a Moderna, Cocrystal pharma, Vaxart e Innovio, se pusieron demasiada especulativas y recogí varias baggers Saludos

**jerez1** · 27/05/2021, 16:22:36

En breve tirón

Tonix Pharmaceuticals Announces Presentation of Two Posters at the 2021 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting

https://finance.yahoo.com/news/tonix-pharmaceuticals-announces-presentation-two-110000085.html

Tonix to Present Posters on TNX-102 SL for Fibromyalgia and PTSDCHATHAM, N.J., May 26, 2021 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company) a clinical-stage biopharmaceutical company, announced that it will present two posters at the 2021 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting. The ASCP annual meeting is being held virtually June 1-4, 2021. Copies of the posters will be made available under the IR Events tab of the Investors section of the Tonix website at the times of the presentations at www.tonixpharma.com. Poster presentation details are as follows: Title Efficacy and Safety of TNX-102 SL (Sublingual Cyclobenzaprine) for the Treatment of Fibromyalgia in the RELIEF Study: Positive Results of a Phase 3 Randomized, Double-Blind, Placebo-Controlled Multicenter TrialSession Poster Session IDate June 2, 2021Time 11:00 a.m. – 12:00 p.m. ET Title Effect of Bedtime Sublingual Cyclobenzaprine (TNX-102 SL) on PTSD Sleep-Dependent Emotional Memory Processing: Retrospective Analysis of Phase 2 and 3 Trial Results in Military-Related and Civilian PTSDSession Poster Session IIDate June 3, 2021Time 10:00 a.m. – 11:00 a.m. ET Tonix Pharmaceuticals Holding Corp. Tonix is a clinical-stage biopharmaceutical company focused on discovering, licensing, acquiring and developing small molecules and biologics to treat and prevent human disease and alleviate suffering. Tonix’s portfolio is primarily composed of central nervous system (CNS) and immunology product candidates. The Company’s CNS portfolio includes both small molecules and biologics to treat pain, neurologic, psychiatric and addiction conditions. Tonix’s lead CNS candidate, TNX-102 SL1, is in mid-Phase 3 development for the management of fibromyalgia, with positive data from the Phase 3 RELIEF study reported in December 2020. The Company expects interim data from the second Phase 3 study, RALLY, in the third quarter of 20212 and topline data in the first quarter of 2022. Tonix’s immunology portfolio includes vaccines to prevent infectious diseases and biologics to address immunosuppression, cancer, and autoimmune diseases. Tonix’s lead vaccine candidate, TNX-18003, is a live replicating vaccine based on the horsepox viral vector platform to protect against COVID-19, primarily by eliciting a T cell response. Tonix reported positive efficacy data from animal studies of TNX-1800 in the first quarter of 2021. TNX-8013, live horsepox virus vaccine for percutaneous administration, is in development to protect against smallpox and monkeypox. 1TNX-102 SL is an investigational new drug and has not been approved for any indication. 2Pending agreement from FDA on statistical analysis plan. 3TNX-1800 and TNX-801 are investigational new biologics and have not been approved for any indication. This press release and further information about Tonix can be found at www.tonixpharma.com. Forward Looking Statements Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as “anticipate,” “believe,” “forecast,” “estimate,” “expect,” and “intend,” among others. These forward-looking statements are based on Tonix's current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations; delays and uncertainties caused by the global COVID-19 pandemic; risks related to the timing and progress of clinical development of our product candidates; our need for additional financing; uncertainties of patent protection and litigation; uncertainties of government or third party payor reimbursement; limited research and development efforts and dependence upon third parties; and substantial competition. As with any pharmaceutical under development, there are significant risks in the development, regulatory approval, and commercialization of new products. Tonix does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set forth in the Annual Report on Form 10-K for the year ended December 31, 2020, as filed with the Securities and Exchange Commission (the “SEC”) on March 15, 2021, and periodic reports filed with the SEC on or after the date thereof. All Tonix's forward-looking statements are expressly qualified by all such risk factors and other cautionary statements. The information set forth herein speaks only as of the date thereof. Contacts Jessica Morris (corporate)Tonix [email protected](862) 904-8182 Olipriya Das, Ph.D. (media)Russo [email protected] (646) 942-5588 Peter Vozzo (investors)Westwicke/[email protected](443) 213-0505

**jerez1** · 03/06/2021, 14:49:46

A ver si acompaña la noticia a nuevo tirón

Tonix Pharmaceuticals presenta resultados positivos del estudio RELIEF de fase 3 de TNX-102 SL para el manejo de la fibromialgia en la reunión anual de la Sociedad Americana de Psicofarmacología Clínica (ASCP) de 2021

Estudio confirmatorio de fase 3, RALLY, en curso con análisis intermedio previsto para el tercer trimestre de 2021

3 de junio de 2021 07:00 ET | Fuente: Tonix Pharmaceuticals Holding Corp.

Tonix Pharmaceuticals Presents Positive Results from Phase 3 RELIEF Study of TNX-102 SL for the Management of Fibromyalgia at the 2021 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting

https://www.globenewswire.com/news-release/2021/06/03/2241167/28908/en/Tonix-Pharmaceuticals-Presents-Positive-Results-from-Phase-3-RELIEF-Study-of-TNX-102-SL-for-the-Management-of-Fibromyalgia-at-the-2021-American-Society-of-Clinical-Psychopharmacolo.html

Confirmatory Phase 3 Study, RALLY, Ongoing with Interim Analysis Expected in Third Quarter 2021...

**jerez1** · 04/06/2021, 18:25:40

Empieza el nuevo tirón al alza , +8%

**jerez1** · 07/06/2021, 16:11:37

En cuanto rompa la resi de 1,37, directo a los 2 dólares

Tonix Pharmaceuticals (TNXP) Stock Price | Stock Quote Nasdaq - MarketScreener

https://www.marketscreener.com/quote/stock/TONIX-PHARMACEUTICALS-HOL-47362663/charts/

Tonix Pharmaceuticals (TNXP.NASDAQ) : Stock quote, stock chart, quotes, analysis, advice, financials and news for Stock Tonix Pharmaceuticals | Nasdaq: TNXP | Nasdaq

Tonix Pharmaceutical

Tonix Pharmaceutical

Consulta aquí qué empresas tienen los inversores en sus carteras en las estadísticas de Invertirenbolsa.info

Comentario

Comentario

Comentario

Comentario

Comentario

Comentario

Comentario

Comentario

Comentario